---
title: "Bezuclastinib: Nonadvanced systemic mastocytosis"
description: "Formulary evidence on Bezuclastinib in Nonadvanced systemic mastocytosis. Clinical evidence covers SUMMIT, PIONEER, and WO2024138005A1 example 7. 131 evidence topics quoted from 63 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Bezuclastinib: Nonadvanced systemic mastocytosis

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Bezuclastinib

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Nonadvanced systemic mastocytosis

<a id="topic-1.1.1-1"></a>

##### Summary

In the Danish register study, all nonadvanced SM was classified as ISM; prevalence on January 1, 2022 was 9.36 per 100,000. In a U.S. survey of people with SM, 54% reduced work hours and 64% avoided leaving home because of symptoms. These survey estimates are not specific to nonadvanced disease. A separate matched-control study reported mean post-index medical costs of $24,588 for nonadvanced SM versus $14,419 for controls.

Source: [Jørgensen et al. (2025)](https://link.springer.com/article/10.1007/s10654-024-01195-5); [Mesa et al. (2022a)](https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34420); [Norregaard et al. (2021)](https://www.blueprintmedinfo.com/uploads/AMCP-2021.-Non-advanced-SM-poster_.pdf)

<a id="heading-1.1.2"></a>

#### 1.1.2 Bezuclastinib Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

SUMMIT Part 2 randomized 179 participants, 119 to bezuclastinib and 60 to placebo. Reported mean TSS reductions at week 24 were 24.3 and 15.4 points, respectively (p=0.0002). At least 50% TSS reduction occurred in 34.3% versus 18.1%. In the intention-to-treat biomarker analysis, at least 50% serum tryptase reduction occurred in 104/119 participants (87.4%) versus 0/60. Hair color change occurred in 69.5% versus 5.0%; ALT/AST elevations occurred in 22.0% versus 6.6%. Treatment-related discontinuations occurred in 5.9% of bezuclastinib recipients, all due to transaminase elevations that subsequently resolved.

Source: [Rein et al. (2026a)](https://ncoda.org/nohma/2026isf-a25p25/); [Cogent Biosciences SUMMIT top-line results announcement (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-positive-top-line-results-achieving); [Cogent Biosciences SUMMIT full results announcement at ASH (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-presents-full-summit-results-bezuclastinib); [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/64526478-fe1c-4965-8329-5918e4aa5d78)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Bezuclastinib

No evidence found.

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

Bezuclastinib remains investigational in the regulatory evidence reproduced here. The FDA review announcement gives a December 30, 2026 target action date. SUMMIT provides placebo-controlled evidence of symptom and biomarker improvement, with transaminase elevations contributing to treatment discontinuation. The effect of KIT inhibition on disease progression remains uncertain. Comparator avapritinib evidence does not establish a direct comparison with bezuclastinib.

Source: [FDA orphan drug designation record for bezuclastinib (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=929722); [Cogent Biosciences NonAdvSM new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-application); [Rein et al. (2026a)](https://ncoda.org/nohma/2026isf-a25p25/); [Cogent Biosciences SUMMIT top-line results announcement (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-positive-top-line-results-achieving); [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/64526478-fe1c-4965-8329-5918e4aa5d78); [Syal et al. (2025)](https://link.springer.com/article/10.1007/s00277-025-06475-y); [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/)

## Related pages
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Terms and abbreviations](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/terms-and-abbreviations.md)
- [Bezuclastinib: Nonadvanced systemic mastocytosis](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/executive-summary.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Product information and disease description](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/product-information-and-disease-description.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Clinical evidence](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/clinical-evidence.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Economic information and modeling report](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/economics) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/economics.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: References](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/references) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/references.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: prevalence by geography](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/prevalence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/prevalence.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/cost-effectiveness-analyses.md)
